Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback